Eye Catching Stocks: CEL-SCI Corporation (CVM), Intel Corporation (INTC), HP Inc. (HPQ)

CEL-SCI Corporation (CVM) managed to rebound with the stock climbing 38.86% or $0.05 to close the day at $0.16 on active trading volume of 16.73M shares, compared to its three month average trading volume of 1.77M. The Vienna Virginia 22182 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -58.16%, compared to the industry which has dropped -0.36% over the same period. With RSI of 64.12, the stock should still continue to rise and get closer to its one year target estimate of $3, making it a hold for now.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Intel Corporation (INTC) fell -0.19% during last trading as the stock lost $-0.07 to finish the day at $36.54 with about 15.9M shares changing hands, compared to its three month average trading volume of 20.44M. The $172.98B market cap company, which fluctuated between $36.53 and $36.93 during the day, currently situated 35.17% above its 52 week low of $27.68 and -4.02% away from its one year high of $38.36. The RSI of 55.35 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Intel Corporation designs, manufactures, and sells integrated digital technology platforms worldwide. It operates through Client Computing Group, Data Center Group, Internet of Things Group, Software and Services, and All Other segments. The company’s platforms are used in various computing applications comprising notebooks, 2 in 1 systems, desktops, servers, tablets, smartphones, wireless and wired connectivity products, wearables, retail devices, and manufacturing devices, as well as for retail, transportation, industrial, buildings, home use, and other market segments. It offers microprocessors that processes system data and controls other devices in the system; chipsets, which send data between the microprocessor and input, display, and storage devices, such as keyboard, mouse, monitor, hard drive or solid-state drive, and optical disc drives; and system-on-chip products that integrate its central processing units with other system components onto a single chip. The company also provides communication and connectivity offerings, such as baseband processors, radio frequency transceivers, and power management integrated circuits; and tablet, phone, and Internet of Things solutions, which include multimode 4G LTE modems, Bluetooth technology and GPS receivers, software solutions, and interoperability tests, as well as home gateway and set-top box components. In addition, it offers security solutions for computers, mobile devices, and networks, as well as software and services for technology integration; NAND flash memory products, which are used in solid-state drives; and custom foundry services, including custom silicon, packaging, and manufacturing test services. The company sells its products primarily to original equipment manufacturers, original design manufacturers, and industrial and communications equipment manufacturers in the computing and communications industries. Intel Corporation was founded in 1968 and is based in Santa Clara, California.

HP Inc. (HPQ) saw its value increase by 0.07% as the stock gained $0.01 to finish the day at a closing price of $14.69. The stock was higher in trading and has fluctuated between $8.91-$16.25 per share for the past year. The shares, which traded within a range of $14.4 to $14.97 during the day, are down by -4.97% in the past three months and up by 8.94% over the past six months. It is currently trading -3.25% below its 20 day moving average and -3.18% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $16.1 a share over the next twelve months. The current relative strength index (RSI) reading is 37.73. The technical indicator lead us to believe there will be no major movement any time soon, hold.

HP Inc. provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses, as well as to the government, health, and education sectors worldwide. It operates through Personal Systems and Printing segments. The Personal Systems segment offers commercial personal computers (PCs), consumer PCs, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, media, solutions, and services, as well as scanning devices; and laserjet and enterprise, inkjet and printing, graphics, and 3D printing solutions. The company was formerly known as Hewlett-Packard Company and changed its name to HP Inc. in October 2015. HP Inc. was founded in 1939 and is headquartered in Palo Alto, California.

 

Stocks Alert: KeyCorp (KEY), CEL-SCI Corporation (CVM), Macy’s, Inc. (M)

KeyCorp (KEY) retreated with the stock falling -0.33% or $-0.06 to close at $18.26 on active trading volume of 9.48M compared its three months average trading volume of 15.9M. The Cleveland Ohio 44114 based company operating under the Regional – Midwest Banks industry has been trending up for the last 52 weeks, with the shares price now 57.2% up for the period and down by -0.05% so far this year. With price target of $18.88 and a 89.65% rebound from 52-week low, KeyCorp has plenty of upside potential, making it a hold with a view buy.

KeyCorp operates as the bank holding company for KeyBank National Association that provides various retail and commercial banking services to individual, corporate, and institutional clients in the United States. The company’s Key Community Bank segment offers deposit and investment products; personal finance services and loans, including residential mortgages, home equity, credit cards, and various installment loans for individuals; deposits, investment and credit products, and business advisory services to small businesses; and financial, estate and retirement planning, and asset management services to high-net-worth clients. This segment also provides commercial lending, cash management, equipment leasing, investment and employee benefit programs, succession planning, access to capital markets, derivatives, and foreign exchange services to mid-sized businesses. Its Key Corporate Bank segment offers a suite of banking and capital market products, such as syndicated finance, debt and equity capital market products, commercial payments, equipment finance, commercial mortgage banking, derivatives, foreign exchange, financial advisory, and public finance, as well as commercial mortgage loans for middle market clients comprising consumer, energy, healthcare, industrial, public, real estate, and technology sectors. In addition, KeyCorp provides personal, securities lending, and custody services; access to mutual funds; treasury, investment banking, international banking, and investment management services; public retirement plans, and foundations and endowments plans; and financial services consisting of community development financing, securities underwriting, and brokerage, as well as merchant services. As of December 31, 2015, the company operated 966 retail banking branches and 1,257 automated teller machines in 12 states, as well as a telephone banking call center. KeyCorp was founded in 1849 and is headquartered in Cleveland, Ohio.

CEL-SCI Corporation (CVM) dropped $0 to close the day at a new closing price of $0.11, a 1.78% increase in value from its previous closing price that moved the stock 90.83% above its 52 week low of $0.06. A total of 9.38M shares exchanged hands during the day compared with its three month average trading volume of 1.63M. The stock, which fluctuated between $0.105 and $0.12 during the day, currently situated -82.65% below its 52 week high. The stock is down by -4.58% in the past one month and down by -59.11% over the past three months. With a one year target estimate of $3 and RSI of 49.36, the stock still has upside potential, making it a hold for now.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Macy’s, Inc. (M) shares were down in last trading by -1.17% to $30.46. It experienced higher than average volume on day. The stock decreased in value by almost -14.94% over the past week and fell -28.79% in the past month. It is currently trading -21.86% below its 50 day moving average and -16.35% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -32.29% decrease in value from its one year high of $45.5. The RSI indicator value of 22.03, lead us to believe that it may correct downwards in the near term.

Macy’s, Inc., together with its subsidiaries, operates stores, Websites, and mobile applications in the United States. Its stores and Websites sell a range of merchandise, including apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates stores that offer a range of women’s, men’s, and children’s apparel; shoes; fashion accessories; housewares; home textiles; intimate apparel; and jewelry. As of November 14, 2016, it operated approximately 870 stores under the Macy’s, Bloomingdales, Bluemercury, Bloomingdale’s Outlet, and Macy’s Backstage brands, as well as Websites, including macys.com, bloomingdales.com, and bluemercury.com. In addition, it operates as a beauty products and spa retailer. The company was formerly known as Federated Department Stores, Inc. and changed its name to Macy’s, Inc. in June 2007. Macy’s, Inc. was founded in 1830 and is based in Cincinnati, Ohio.

 

Stocks Roundup: Netflix, Inc. (NFLX), Kohl’s Corporation (KSS), CEL-SCI Corporation (CVM)

Netflix, Inc. (NFLX) retreated with the stock falling -0.56% or $-0.74 to close at $131.07 on light trading volume of 10.65M compared its three months average trading volume of 8.51M. The Los Gatos California 95032 based company operating under the CATV Systems industry has been trending up for the last 52 weeks, with the shares price now 14.41% up for the period and up by 5.87% so far this year. With price target of $124.35 and a 63.94% rebound from 52-week low, Netflix, Inc. has plenty of upside potential, making it a hold with a view buy.

Netflix, Inc., an Internet television network, engages in the Internet delivery of television (TV) shows and movies on various Internet-connected screens. The company operates in three segments: Domestic streaming, International streaming and Domestic DVD. It offer members with the ability to receive TV shows and movies streaming content, including original series, documentaries, and feature films through a host of Internet-connected screens, such as TVs, digital video players, TV set-top boxes, and mobile devices. The company also provides DVDs-by-mail membership services. As of October 17, 2016, it served approximately 86 million streaming members in 190 countries. Netflix, Inc. was founded in 1997 and is headquartered in Los Gatos, California.

Kohl’s Corporation (KSS) had a light trading with around 10.34M shares changing hands compared to its three month average trading volume of 4.32M. The stock traded between $41.17 and $42.1 before closing at the price of $41.43 with -1.38% change on the day. The Menomonee Falls Wisconsin 53051 based company is currently trading 26.52% above its 52 week low of $33.87 and -30.57% below its 52 week high of $59.67. Both the RSI indicator and target price of  and $51.95 respectively, lead us to believe that it could rise over the coming weeks.

Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers. The company also sells its products online through Website Kohls.com. As of January 30, 2016, it operated 1,164 department stores in 49 states. Kohl’s Corporation was founded in 1962 and is headquartered in Menomonee Falls, Wisconsin.

CEL-SCI Corporation (CVM) saw its value increase by 37.87% as the stock gained $0.03 to finish the day at a closing price of $0.11. The stock was higher in trading and has fluctuated between $0.06-$0.66 per share for the past year. The shares, which traded within a range of $0.0817 to $0.1179 during the day, are down by -58.33% in the past three months and down by -76.06% over the past six months. It is currently trading 23.67% above its 20 day moving average and -38.52% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $3 a share over the next twelve months. The current relative strength index (RSI) reading is 49.02.The technical indicator lead us to believe there will be no major movement any time soon, hold.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

 

3 Stocks in Focus: Macy’s, Inc. (M), CEL-SCI Corporation (CVM), Ares Capital Corporation (ARCC)

Macy’s, Inc. (M) fell -1.32% during last trading as the stock lost $-0.48 to finish the day at $35.81 with about 3.78M shares changing hands, compared to its three month average trading volume of 5.86M. The $11.09B market cap company, which fluctuated between $35.61 and $36.5 during the day, currently situated 23.43% above its 52 week low of $29.94 and -20.4% away from its one year high of $45.5. The RSI of 32.86 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Macy’s, Inc., together with its subsidiaries, operates stores, Websites, and mobile applications in the United States. Its stores and Websites sell a range of merchandise, including apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates stores that offer a range of women’s, men’s, and children’s apparel; shoes; fashion accessories; housewares; home textiles; intimate apparel; and jewelry. As of November 14, 2016, it operated approximately 870 stores under the Macy’s, Bloomingdales, Bluemercury, Bloomingdale’s Outlet, and Macy’s Backstage brands, as well as Websites, including macys.com, bloomingdales.com, and bluemercury.com. In addition, it operates as a beauty products and spa retailer. The company was formerly known as Federated Department Stores, Inc. and changed its name to Macy’s, Inc. in June 2007. Macy’s, Inc. was founded in 1830 and is based in Cincinnati, Ohio.

CEL-SCI Corporation (CVM) dropped $0 to close the day at a new closing price of $0.07, a -10.28% decrease in value from its previous closing price that moved the stock 12% above its 52 week low of $0.06. A total of 3.78M shares exchanged hands during the day compared with its three month average trading volume of 1.37M. The stock, which fluctuated between $0.0645 and $0.076 during the day, currently situated -89.82% below its 52 week high. The stock is down by -68% in the past one month and down by -78.32% over the past three months. With a one year target estimate of $3 and RSI of 18.1, the stock still has upside potential, making it a buy for now.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Ares Capital Corporation (ARCC) had a active trading with around 3.78M shares changing hands compared to its three month average trading volume of 2.34M. The stock traded between $16.33 and $16.66 before closing at the price of $16.49 with -0.42% change on the day. The New York New York 10167 based company is currently trading 48.21% above its 52 week low of $12.31 and -0.54% below its 52 week high of $16.91. Both the RSI indicator and target price of 67.07 and $16.68 respectively, lead us to believe that it should be put on hold over the coming weeks.

 

Stocks Under Consideration: CEL-SCI Corporation (CVM), Zions Bancorporation (ZION), Diamond Offshore Drilling, Inc. (DO)

CEL-SCI Corporation (CVM) retreated with the stock falling -1.58% or $-0.01 to close at $0.07 on active trading volume of 1.55M compared its three months average trading volume of 1.36M. The Vienna Virginia 22182 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -79.76% down for the period and down by -79.76% so far this year. With price target of $3 and a 24.83% rebound from 52-week low, CEL-SCI Corporation has plenty of upside potential, making it a hold with a view buy.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Zions Bancorporation (ZION) had a light trading with around 1.55M shares changing hands compared to its three month average trading volume of 3.21M. The stock traded at the price of $42.79 with -1.13% change on the day. The Salt Lake City Utah 84133 based company is currently trading 119.97% above its 52 week low of $19.65 and -3.08% below its 52 week high of $44.15. Both the RSI indicator and target price of  and $41.56 respectively, lead us to believe that it could rise over the coming weeks.

Zions Bancorporation, a financial holding company, provides a range of banking and related services in Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The company offers community banking services, such as small and medium-sized business and corporate banking; commercial and residential development, construction, and term lending; retail banking; treasury cash management and related products and services; and residential mortgage servicing and lending. It also provides trust and wealth management services; capital markets services, including municipal finance advisory and underwriting; and investment services. In addition, the company offers personal banking services to individuals, including home mortgages, bankcards, other installment loans, home equity lines of credit, checking accounts, savings accounts, certificates of deposit of various types and maturities, safe deposit facilities, direct deposits, and Internet and mobile banking services. Further, it provides online and traditional brokerage services; small business administration and secondary market agricultural real estate mortgage loans; and bond transfer, stock transfer, and escrow services for corporate customers. As of December 31, 2015, the company operated 450 domestic branches. Zions Bancorporation was founded in 1873 and is headquartered in Salt Lake City, Utah.

Diamond Offshore Drilling, Inc. (DO) saw its value increase by 0.17% as the stock gained $0.03 to finish the day at a closing price of $17.88. The stock was lighter in trading and has fluctuated between $14.18-$26.72 per share for the past year. The shares, which traded within a range of $17.73 to $17.98 during the day, are up by 0.34% in the past three months and down by -26.51% over the past six months. It is currently trading -6.95% below its 20 day moving average and 0.9% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $17.34 a share over the next twelve months. The current relative strength index (RSI) reading is 44.16.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Diamond Offshore Drilling, Inc. provides contract drilling services to the energy industry worldwide. It provides services in floater market, including ultra-deepwater, deepwater, and mid-water. The company operates a fleet of 32 offshore drilling rigs, which comprise 8 ultra-deepwater, 7 deepwater, and 8 mid-water semisubmersibles; 5 jack-ups; and 4 drillships. It serves independent oil and gas companies, and government-owned oil companies. The company was founded in 1989 and is headquartered in Houston, Texas. Diamond Offshore Drilling, Inc. operates as a subsidiary of Loews Corporation.

 

Stocks To Watch: Monster Beverage Corporation (MNST), Graphic Packaging Holding Company (GPK), CEL-SCI Corporation (CVM)

Monster Beverage Corporation (MNST) traded within a range of $44.7 to $45.63 after opening the day at $45.63. The company has seen its stock decrease in value by -9.55% so far this year. The stock was down close to -1.36% on light volume in last trading session and closed at $44.91 per share. After the recent fall, the stock is currently holding -19.08% below its 52 week high of $55.5 and 19.15% above its 12-month low of $37.69. The shares are down by over -8.24% in the last three months, and the RSI indicator value of 49.31 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Monster Beverage Corporation, through its subsidiaries, develops, markets, sells, and distributes energy drink beverages and its concentrates in the United States and internationally. It operates through three segments: Finished Products, Concentrate, and Other. The company provides carbonated energy, and non-carbonated dairy based coffee and energy drinks to full service beverage distributors, retail grocery and specialty chains, wholesalers, club stores, drug chains, mass merchandisers, convenience chains, health food distributors, food service customers, and the military; and concentrates and/or beverage bases to authorized bottling and canning operations. Monster Beverage Corporation sells its products under the Monster Energy, Nalu, Monster Rehab, NOS, Monster Energy Extra Strength Nitrous Technology, Full Throttle, Java Monster, Burn, Muscle Monster, Mother, Mega Monster Energy, Ultra, Punch Monster, Play and Power Play, Juice Monster, Gladiator, M3, Relentless, Übermonster, Samurai, BU, and BPM brands. The company was formerly known as Hansen Natural Corporation and changed its name to Monster Beverage Corporation in January 2012. Monster Beverage Corporation was founded in 1985 and is headquartered in Corona, California.

Graphic Packaging Holding Company (GPK) failed to extend gains with the stock declining -1.43% or $-0.18 to close the day at $12.41 on light trading volume of 1.65M shares, compared to its three month average trading volume of 3.82M. The Atlanta Georgia 30328 based company has been underperforming the packaging & containers group over the past 52 weeks, with the stock losing -1.53%, compared to the industry which has advanced 16.71% over the same period. With RSI of 41.83, the stock should still continue to rise and get closer to its one year target estimate of $15.1, making it a hold for now.

Graphic Packaging Holding Company, together with its subsidiaries, provides paper-based packaging solutions to food, beverage, and other consumer products companies. The company operates in three segments: Paperboard Mills, Americas Paperboard Packaging, and Europe Paperboard Packaging. The company offers coated unbleached kraft (CUK) and coated recycled board (CRB) to various paperboard packaging converters and brokers; and paperboard packaging folding cartons primarily to consumer packaged goods companies serving the food, beverage, and consumer product markets. It also manufactures corrugated medium and kraft paper; offers various laminated, coated, and printed packaging structures that are produced from its CUK and CRB, as well as other grades of paperboard that are purchased from third-party suppliers; designs and manufactures specialized packaging machines that package bottles and cans, and non-beverage consumer products; and installs its packaging machines at customer plants and provides support, service, and performance monitoring of the machines. The company markets its product primarily through sales offices and broker arrangements with third parties in the Americas, Europe, and the Asia Pacific. Graphic Packaging Holding Company was founded in 1992 and is headquartered in Atlanta, Georgia.

CEL-SCI Corporation (CVM) dropped $0 to close the day at a new closing price of $0.08, a -1.55% decrease in value from its previous closing price that moved the stock 26.83% above its 52 week low of $0.06. A total of 1.64M shares exchanged hands during the day compared with its three month average trading volume of 1.36M. The stock, which fluctuated between $0.0721 and $0.0882 during the day, currently situated -88.47% below its 52 week high. The stock is down by -70.73% in the past one month and down by -71.81% over the past three months. With a one year target estimate of $3 and RSI of 22.76, the stock still has upside potential, making it a buy for now.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

 

Stocks In Action: Bed Bath & Beyond Inc. (BBBY), Allergan plc (AGN), CEL-SCI Corporation (CVM)

Bed Bath & Beyond Inc. (BBBY) opening the day at $41.3. The company has seen its stock decrease in value by -14.79% so far this year. The stock was down close to -1.47% on active volume in last trading session and closed at $40.77 per share. After the recent fall, the stock is currently holding -22% below its 52 week high of $52.71 and 5.9% above its 12-month low of $38.6. The shares are down by over -3.16% in the last three months, and the RSI indicator value of 30.12 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Bed Bath & Beyond Inc., together with its subsidiaries, operates a chain of retail stores. It sells a range of domestics merchandise, including bed linens and related items, bath items, and kitchen textiles; and home furnishings, such as kitchen and tabletop items, fine tabletop, basic housewares, general home furnishings, consumables, and juvenile products. It also provides various textile products, amenities, and other goods to institutional customers in the hospitality, cruise line, healthcare, and other industries. The company operates stores under the Bed Bath & Beyond (BBB); Christmas Tree Shops; Christmas Tree Shops andThat! or andThat! (CTS); Harmon or Harmon Face Values (Harmon); buybuy BABY (Baby); and World Market, Cost Plus World Market, and Cost Plus (Cost Plus World Market) names. As of February 27, 2016, the company had a total of 1,530 stores, including 1,020 BBB stores; 276 stores under the names of Cost Plus World Market; 105 Baby stores; 78 stores under the CTS names; and 51 stores under the Harmon names in 50 states, the District of Columbia, Puerto Rico, and Canada, as well as through bedbathandbeyond.com, bedbathandbeyond.ca, christmastreeshops.com, andthat.com, harmondiscount.com, facevalues.com, buybuybaby.com, buybuybaby.ca, worldmarket.com, and ofakind.com Websites. In addition, it operates PersonalizationMall.com that offers personalized gifts. Bed Bath & Beyond Inc. was founded in 1971 and is based in Union, New Jersey.

Allergan plc (AGN) managed to rebound with the stock climbing 2.62% or $5.09 to close the day at $199.08 on light trading volume of 4.18M shares, compared to its three month average trading volume of 4.97M. The Dublin Dublin D17 E400 based company has been underperforming the drugs – generic group over the past 52 weeks, with the stock losing -36.03%, compared to the industry which has dropped -27.11% over the same period. With RSI of 54.17, the stock should still continue to rise and get closer to its one year target estimate of $261.63, making it a hold for now.

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, liver disease, inflammation, fibrosis, and HIV, as well as dermatology and plastic surgery, and Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, it distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Allergan plc has a collaboration with T2 Biosystems to develop blood-based diagnostic panel for the detection of Gram-negative bacterial species. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

CEL-SCI Corporation (CVM) dropped $-0.01 to close the day at a new closing price of $0.08, a -13.39% decrease in value from its previous closing price that moved the stock -5.52% below its 52 week low of $0.06. A total of 4.16M shares exchanged hands during the day compared with its three month average trading volume of 1.41M. The stock, which fluctuated between $0.06 and $0.088 during the day, currently situated -88.33% below its 52 week high. The stock is down by -72.5% in the past one month and down by -82.5% over the past three months. With a one year target estimate of $3 and RSI of 22.63, the stock still has upside potential, making it a buy for now.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

 

Equities Trend Analysis: PDL BioPharma, Inc. (PDLI), CEL-SCI Corporation (CVM), Regal Entertainment Group (RGC)

PDL BioPharma, Inc. (PDLI) grew with the stock adding 5.05% or $0.1 to close at $2.08 on light trading volume of 1.93M compared its three months average trading volume of 2.29M. The Incline Village Nevada 89451 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -43.41% down for the period and down by -39.42% so far this year. With price target of $3.5 and a 7.77% rebound from 52-week low, PDL BioPharma, Inc. has plenty of upside potential, making it a hold with a view buy.

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. has license agreements with various biotechnology and pharmaceutical companies, as well as acquires royalty and other assets. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

CEL-SCI Corporation (CVM) had a active trading with around 1.92M shares changing hands compared to its three month average trading volume of 1.37M. The stock traded between $0.0815 and $0.095 before closing at the price of $0.09 with -6.91% change on the day. The Vienna Virginia 22182 based company is currently trading -4.78% below its 52 week low of $0.08 and -86.73% below its 52 week high of $0.66. Both the RSI indicator and target price of  and $3 respectively, lead us to believe that it could rise over the coming weeks.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Regal Entertainment Group (RGC) saw its value increase by 1.33% as the stock gained $0.28 to finish the day at a closing price of $21.32. The stock was higher in trading and has fluctuated between $16.5-$24.79 per share for the past year. The shares, which traded within a range of $21 to $21.4 during the day, are down by -0.29% in the past three months and up by 5.68% over the past six months. It is currently trading -2.97% below its 20 day moving average and -4.24% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $23.86 a share over the next twelve months. The current relative strength index (RSI) reading is 42.29.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Regal Entertainment Group, through its subsidiaries, operates as a motion picture exhibitor in the United States. It develops, acquires, and operates multi-screen theatres primarily in mid-sized metropolitan markets and suburban growth areas of larger metropolitan markets. The company operates a theatre circuit under the brands of Regal Cinemas, United Artists, Edwards, Great Escape Theatres, and Hollywood Theaters. As of September 01, 2016, it operated 7, 307 screens in 564 theatres in 42 states along with Guam, Saipan, American Samoa, and the District of Columbia. Regal Entertainment Group was founded in 2002 and is based in Knoxville, Tennessee.

 

Equities Trend Analysis: Electronic Arts Inc. (EA), CEL-SCI Corporation (CVM), Under Armour, Inc. (UA)

Electronic Arts Inc. (EA) grew with the stock adding 1% or $0.81 to close at $81.51 on active trading volume of 3.96M compared its three months average trading volume of 3.18M. The Redwood City California 94065 based company operating under the Multimedia & Graphics Software industry has been trending up for the last 52 weeks, with the shares price now 13.15% up for the period and up by 18.61% so far this year. With price target of $92.63 and a 53.76% rebound from 52-week low, Electronic Arts Inc. has plenty of upside potential, making it a hold with a view buy.

Electronic Arts Inc. develops, markets, publishes, and distributes games, content, and services for consoles, personal computers, mobile phones, and tablets worldwide. It develops and publishes digital interactive entertainment games primarily under the FIFA, Madden NFL, Star Wars, Battlefield, The Sims, Need for Speed, Mass Effect, Dragon Age, Plants vs. Zombies, and Titanfall brand names. The company also offers casual games, such as cards, puzzles, and word games through its Pogo online service. Electronic Arts Inc. was founded in 1982 and is headquartered in Redwood City, California.

CEL-SCI Corporation (CVM) had a active trading with around 3.94M shares changing hands compared to its three month average trading volume of 1.27M. The stock traded between $0.092 and $0.104 before closing at the price of $0.09 with -11.57% change on the day. The Vienna Virginia 22182 based company is currently trading 0.21% above its 52 week low of $0.092 and -85.76% below its 52 week high of $0.66. Both the RSI indicator and target price of  and $3 respectively, lead us to believe that it could rise over the coming weeks.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Under Armour, Inc. (UA) saw its value decrease by -2.9% as the stock dropped $-0.77 to finish the day at a closing price of $25.8. The stock was lighter in trading and has fluctuated between $23.51-$46.21 per share for the past year. The shares, which traded within a range of $25.5 to $26.79 during the day, are down by -33.69% in the past three months and down by -30.68% over the past six months. It is currently trading -13.9% below its 20 day moving average and -21.11% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $37.88 a share over the next twelve months. The current relative strength index (RSI) reading is 25.51.The technical indicator lead us to believe the stock will reverse recent losses any time soon.

Under Armour, Inc. together with its subsidiaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company offers its apparel in compression, fitted, and loose types to be worn in hot, cold, and in between the extremes. It provides various footwear products, including football, baseball, lacrosse, softball and soccer cleats, slides, performance training, running, basketball, and outdoor footwear. The company also offers accessories, which include headwear, bags, and gloves; and digital fitness platform licenses and subscriptions, as well as digital advertising, as well as licenses its brands. It primarily provides its products under the UA Logo, UNDER ARMOUR, UA, ARMOUR, HEATGEAR, COLDGEAR, ALLSEASONGEAR, PROTECT THIS HOUSE, and I WILL, as well as ARMOURBITE, ARMOURSTORM, ARMOUR FLEECE, and ARMOUR BRA trademarks. The company sells its products through wholesale channels, including national and regional sporting goods chains, independent and specialty retailers, department store chains, institutional athletic departments, and leagues and teams, as well as independent distributors; and directly to consumers through a network of brand and factory house stores, and Website. Under Armour, Inc. was founded in 1996 and is headquartered in Baltimore, Maryland.

 

Stocks Trend Analysis: CEL-SCI Corporation (CVM), GNC Holdings, Inc. (GNC), HollyFrontier Corporation (HFC)

CEL-SCI Corporation (CVM) managed to rebound with the stock declining 2.01% or $0 to close the day at $0.1 on active trading volume of 2.62M shares, compared to its three month average trading volume of 1.21M. The Vienna Virginia 22182 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -75.24%, compared to the industry which has dropped -6.01% over the same period. With RSI of 22.65, the stock should still continue to rise and get closer to its one year target estimate of $3, making it a hold for now.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company, through its LEAPS technology, provides peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

GNC Holdings, Inc. (GNC) retreated with the stock falling -3.88% or $-0.54 to close at $13.37 on active trading volume of 2.62M compared its three months average trading volume of 2.35M. The Pittsburgh Pennsylvania 15222 based company operating under the Drug Stores industry has been trending down for the last 52 weeks, with the shares price now -54.72% down for the period and down by -55.85% so far this year. With price target of $14.83 and a 4.62% rebound from 52-week low, GNC Holdings, Inc. has plenty of upside potential, making it a hold with a view buy.

GNC Holdings, Inc., together with its subsidiaries, operates as a specialty retailer of health, wellness, and performance products. The company operates through three segments: Retail, Franchise, and Manufacturing/Wholesale. Its products include vitamins, minerals, and herbal supplement products; and sports nutrition products, diet products, and other wellness products. The company sells its products under the GNC proprietary brands, including Mega Men, Ultra Mega, Total Lean, Pro Performance, Pro Performance AMP, Beyond Raw, GNC Puredge, GNC GenetixHD, and Herbal Plus, as well as under third-party brands. It operates a network of approximately 9,000 locations under the GNC brand worldwide. The company sells its products through company-owned retail stores; Websites, including GNC.com and LuckyVitamin.com, as well as Drugstore.com; domestic and international franchise activities; third-party contract manufacturing; and e-commerce and corporate partnerships. GNC Holdings, Inc. was founded in 1935 and is headquartered in Pittsburgh, Pennsylvania.

HollyFrontier Corporation (HFC) managed to rebound with the stock climbing 0.86% or $0.28 to close the day at $32.66 on lower than average trading volume of 2.6M shares, compared to its three month average trading volume of 3.92M. The Dallas Texas 75201 based company has been outperforming the oil & gas refining & marketing companies by 36.8% for last three months and its recent gains have offset losses to -14.36% YTD, versus the oil & gas refining & marketing industry which is up 1.17% for the same period. The RSI of 69.65 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

HollyFrontier Corporation operates as an independent petroleum refiner in the United States. The company operates in two segments, Refining and HEP. It primarily produces high-value refined products, such as gasoline, diesel fuel, jet fuel, specialty lubricant products, liquid petroleum gas, fuel oil, and specialty and modified asphalt. The company offers its products to other refiners, convenience store chains, independent marketers, retailers, truck stop chains, wholesalers, railroads, governmental entities, paving contractors or manufacturers, and commercial and specialty markets, as well as for commercial airline use. It owns and operates five refineries with a combined crude oil processing capacity of approximately 443,000 barrels per day in El Dorado, Kansas; Tulsa, Oklahoma; Artesia, New Mexico; Cheyenne, Wyoming; Woods Cross, Utah, as well as owns and operates asphalt terminals in Arizona, New Mexico, and Oklahoma; and vacuum distillation and other facilities in Lovington, New Mexico. HollyFrontier Corporation’s refineries serve markets in the Mid-Continent, Southwest, and Rocky Mountain regions of the United States. The company was formerly known as Holly Corporation and changed its name to HollyFrontier Corporation as a result of its merger with Frontier Oil Corporation in July 2011. HollyFrontier Corporation was founded in 1947 and is based in Dallas, Texas.